|
| 产地 | 中国 |
| 品牌 | Chemstan |
| 货号 | LC-01 |
| 用途 | 中间体 |
| 包装规格 | 20mg |
| 纯度 | 98%% |
| CAS编号 | 915087-33-1 |
| 是否进口 | 否 |
联合知名大学科研院所及企业开发药食两用植物标准品和天然植物有效单体，主打中药对照品/标准品/天然植物有效单体，小分子化合物库，药物杂质。所有产品仅用作科学研究，我们不为任何个人用途提供产品和服务。
| 常用名 | 恩杂鲁胺 | 英文名 | Enzalutamide |
|---|---|---|---|
| CAS号 | 915087-33-1 | 分子量 | 464.436 |
| 密度 | 1.5±0.1 g/cm3 | 沸点 | N/A |
| 分子式 | C21H16F4N4O2S | 熔点 | N/A |
| MSDS | N/A | 闪点 | N/A |
Enzalutamide (MDV3100) 是一种雄激素受体 (androgen receptor (AR)) 拮抗剂，在LNCaP前列腺细胞中抑制AR 的 IC50 值为36 nM。
Fields of Application :
MDV3100 is an androgen-receptor (AR) antagonist with IC50 of 36 nM.
| CAS Number: | 915087-33-1 |
| Purity: | >98% |
| Molecular Weight: | 464.43 |
| Molecular Formula: | C21H16F4N4O2S |
Quality Control: HPLC、NMR、 LC/MS(Please contact us to get the QC report)
| Synonyms: | MDV-3100; MDV 3100. Enzalutamide, brand name: Xtandi. |
| Chemical Name: | |
| Storage: | 2 years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSO |
Note: Products for research use only, not for human use
Description:
MDV3100 is an orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, selective androgen receptor modulator MDV3100 inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. AR over-expression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance. MDV3100 was discovered by Charles Sawyers who is now at Memorial Sloan–Kettering Cancer Center and Michael Jung at UCLA. MDV3100 is an experimental androgen receptor antagonist drug developed by the pharmaceutical company Medivation For the treatment of castration-resistant prostate cancer currently in Phase 3 clinical trials. Results so far have been encouraging; Medivation has reported up to an 89% decrease in prostate specific antigen serum levels after a month of taking the medicine. Early preclinical studies also suggest that MDV3100 inhibits breast cancer cell growth.For the detailed information of Enzalutamide (MDV3100), the solubility of Enzalutamide (MDV3100) in water, the solubility of Enzalutamide (MDV3100) in DMSO, the solubility of Enzalutamide (MDV3100) in PBS buffer, the animal experiment (test) of Enzalutamide (MDV3100), the cell expriment (test) of Enzalutamide (MDV3100), the in vivo, in vitro and clinical trial test of Enzalutamide (MDV3100), the EC50, IC50,and Affinity of Enzalutamide (MDV3100), Please contact DC Chemicals.
